Nuvilex Names Kenneth L. Waggoner as President and CEO

Nuvilex NVLX today announced that Kenneth L. Waggoner, Esq. has been appointed Chief Executive Officer and President and that Dr. Robert F. Ryan, M.S., Ph.D., has been appointed Chief Science Officer. Mr. Waggoner will head the day to day operations of Nuvilex and provide its strategic direction and corporate focus. Mr. Waggoner, a well-known attorney and recognized leader in the chemical, petroleum and telecommunications industries, will apply his business expertise to strengthen the management team and will focus on bringing Nuvilex's products to market. "I'm delighted to be taking on this role with Nuvilex and look forward to maximizing the value of Nuvilex for both patients and shareholders," said Mr. Waggoner. "With the recent acquisition of the exclusive, worldwide licenses to use the cellulose-based live-cell encapsulation technology for the development of treatments for cancer and diabetes, Nuvilex is in a strong position and poised to bring new therapies for these devastating diseases to market,"  Mr. Waggoner went on to say, "The Nuvilex portfolio is diverse and wide-ranging, and we are fortunate to have See full press release